GLP-1 receptor – Talk Bio

Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment

1 week ago talkbio0Tagged Danuglipron, GLP-1 receptor, GLP-1/GIP therapies, Injury of liver, Metabolic Diseases, Obesity, Pfizer, Pharmaceutical competition, pipeline, Weight-Loss Agents

Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline

FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

3 months ago talkbio0Tagged Agonist, Approved, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes, GLP-1 receptor, Kidney Diseases, Ozempic, Risk, semaglutide, United States Food and Drug Administration

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist

Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction

3 months ago talkbio0Tagged Agonist, enobosarm, GLP-1 receptor, Lean mass preservation, Obesity, sarcopenic, semaglutide, Wegovy, Weight Loss

Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist

Metsera Raises $275M in IPO to Advance GLP-1 Weight Loss Drug to Phase 3

3 months ago talkbio0Tagged Clinical Trials, GLP-1 receptor, IPO, MET-097i, Metsera, Obesity, Weight-Loss Agents

Metsera, IPO, GLP-1 receptor agonist, MET-097i, obesity treatment, weight loss drug, clinical trials, biotech funding

Regor’s Obesity Pill RGT-075 Shows Moderate Weight Loss in Phase 2a, Advances to Phase 2b Trial

3 months ago talkbio0Tagged GLP-1 receptor, Obesity, Oral Medication, phase 2a, Phase 2b Trial, RGT-075

RGT-075, obesity treatment, GLP-1 receptor agonist, oral medication, Phase 2a results, Phase 2b trial

FDA Approves First Generic Version of Victoza (Liraglutide) for Type 2 Diabetes Treatment

4 months ago talkbio0Tagged Approved, Diabetes Mellitus, Non-Insulin-Dependent, GLP-1 receptor, liraglutide, medication options, United States Food and Drug Administration, Victoza

FDA approval, generic Victoza, liraglutide, GLP-1 receptor agonist, Type 2 diabetes treatment, affordable medication options

Merck & Co. Enters Oral GLP-1 Market with $2 Billion Hansoh Pharma Deal

4 months ago talkbio0Tagged GLP-1 receptor, Hansoh Pharma, Merck & Co., Obesity, Oral cavity, Partnership, pharmaceutical collaboration

Merck & Co., Hansoh Pharma, GLP-1 receptor agonist, oral obesity treatment, pharmaceutical collaboration, biotech partnership

Novo Nordisk and Ascendis Pharma Collaborate on Groundbreaking Once-Monthly GLP-1 Treatment for Obesity and Type 2 Diabetes

6 months ago talkbio0Tagged Ascendis, Cardiovascular system, GLP-1 receptor, Metabolic Diseases, Nordisk, Obesity, once-monthly, Pharma, Technology, TransCon

Novo Nordisk, Ascendis Pharma, GLP-1 receptor agonist, once-monthly treatment, obesity, type 2 diabetes, metabolic diseases, cardiovascular therapies, TransCon technology.

Enhancing GI Tolerability of GLP-1 Receptor Agonists: A Path to Improved Therapeutic Outcomes

6 months ago talkbio0Tagged Administration occupational activities, agonists, Diabetes, gastrointestinal tolerability, GLP-1 receptor, Obesity, therapeutic strategies

GLP-1 receptor agonists, gastrointestinal tolerability, therapeutic strategies, diabetes management, obesity treatment